Lemoxol (Ceftazidime)

Ceftazidime interferes with bacterial cell‑wall synthesis by binding to penicillin‑binding proteins. This blocks the cross‑linking of peptidoglycan strands, weakening the wall and causing the bacterium to burst, which results in a rapid bactericidal effect against susceptible Gram‑negative organisms.

The dosage of Lemoxol is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function, and other clinical factors. Healthcare providers set the exact amount, frequency, and duration of therapy.

Lemoxol is classified as pregnancy category B, indicating that animal studies have not shown risk to the fetus and there are no well‑controlled human studies. It should be used only if the potential benefit justifies any possible risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order Lemoxol, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lemoxol (ceftazidime) is a third‑generation cephalosporin with enhanced activity against Pseudomonas aeruginosa and other resistant Gram‑negative bacteria, unlike many earlier‑generation cephalosporins. Its broad spectrum and stability against beta‑lactamases make it a preferred option for serious hospital‑acquired infections, though it may have a higher risk of certain adverse effects compared with some newer agents.

Lemoxol should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken vigorously. Once reconstituted, the solution should be used within the time frame specified in the product labeling and kept under the same temperature conditions until administration.

Lemoxol is supplied as a sterile injectable solution for intramuscular or intravenous administration. The route, infusion rate, and dilution are determined by the prescribing clinician based on the infection being treated and patient-specific factors such as renal function.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome or toxic epidermal necrolysis, Clostridioides difficile‑associated colitis, seizures (especially in patients with renal impairment), and significant renal toxicity when combined with other nephrotoxic drugs.

Lemoxol should be avoided in patients with a documented hypersensitivity to ceftazidime, other cephalosporins, or penicillins. Caution is also advised for individuals with severe renal impairment, a history of severe allergic reactions, or those receiving concurrent nephrotoxic medications.